ARCHIVE ISSUES – MARCH 2023
Drugmakers Still Betting on Anti-Amyloid Approach in Alzheimer’s Amid Skepticism
Less-Buzzy JP Morgan Still Provides Insights Into Companies’ Precision Medicine Plans
Rare Single-Gene Variants Confer High Risk for Mentalm Health Conditions, Geisinger Study Shows
Genomic Medicine Adoption May Be Hindered by Shortcomings in ICD-10 Coding
PGx Testing Reduces Adverse Drug Events, Multi-Site European Study Finds
Biogen Must Prove Tofersen in Genetically Defined ALS, Establish New Surrogate Endpoint
Dried Blood Spots as a Suitable Matrix for Phenotyping the Metabolome: A Proof of Concept Study
Review of the Role of Biostatistics in the Life Cycle of Commercial Molecular Diagnostic Assays
Assessing Measurable Residual Disease as a Genetic Biomarker for Acute Myeloid Leukemia
Unlocking Precision Neuroscience and R&D Innovation for Chronic Diseases
